8
Treatment
Table 1. Summary of Recommendations on Drugs for Use
in a Treatment Regimen for Patients with MDR-TB,
Including Strength of Recommendation, Certainty
in the Evidence and Relative Effects on Death and
Treatment Success
Drug/Drug
Class
Recommendation
Certainty
in the
evidence
Relative
(95% CI)
Death
Relative
(95% CI)
Success
a
FOR AGAINST
Bedaquiline Strong Very Low aOR 0.4
(0.3–0.5)
aOR 2.0
(1.4–2.9)
Fluoroquinolone:
Moxifloxacin
Strong Very Low aOR 0.5
(0.4–0.6)
aOR 3.8
(2.8–5.2)
Fluoroquinolone:
Levofloxacin
Strong Very Low aOR 0.6
(0.5–0.7)
aOR 4.2
(3.3–5.4)
Linezolid Conditional Very Low aOR 0.3
(0.2–0.3)
aOR 3.4
(2.6–4.5)
Clofazimine Conditional Very Low aOR 0.8
(0.6–1.0)
aOR 1.5
(1.1–2.1)
Cycloserine Conditional Very Low aOR 0.6
(0.5–0.6)
aOR 1.5
(1.4–1.7)
Injectables:
Amikacin
Conditional Very Low aOR 1.0
(0.8–1.2)
aOR 2.0
(1.5–2.6)
Injectables:
Streptomycin
Conditional Very Low aOR 0.8
(0.6–1.1)
aOR 1.5
(1.1–2.1)
Ethambutol Conditional Very Low aOR 1.0
(0.9–1.2)
aOR 0.9
(0.7–1.1)
Pyrazinamide Conditional Very Low aOR 0.7
(0.6–0.8)
aOR 0.7
(0.5–0.9)
Carbapenems w/
clavulanic acid
Conditional Very Low aOR 1.0
(0.5–1.7)
aOR 4.0
(1.7–9.1)
Delamanid Concur with WHO conditional recommendation
Ethionamide
Prothionamide
Conditional Very Low aOR 0.9
(0.8–1.0)
aOR 0.8
(0.7–0.9)
Injectables:
Kanamycin
Conditional Very Low aOR 1.1
(0.9–1.2)
aOR 0.5
(0.4–0.6)
P-Aminosalicylic
Acid
Conditional Very Low aOR 1.2
(1.1–1.4)
aOR 0.8
(0.7–1.0)
Injectables:
Capreomycin
Conditional Very Low aOR 1.4
(1.1–1.7)
aOR 0.8
(0.6–1.1)
Macrolides:
Azithromycin
Clarithromycin
Strong Very Low aOR 1.6
(1.2–2.0)
aOR 0.6
(0.5–0.8)
Amoxicillin-
clavulanate
Strong Very Low aOR 1.7
(1.3–2.1)
aOR 0.6
(0.5–0.8)
a
Success defined as end of treatment cure or treatment completion
